Skip to main content
  • About
  • Policy Issues
  • Scientific Innovation
  • Patient Support
  • News
  • Resources
  • Blog
Sites
  • Innovation.org
  • MAT.org
  • PhRMA.org
Exit Search
Exit Search
  • About
  • Policy Issues
  • Scientific Innovation
  • Patient Support
  • News
  • Resources
  • Blog
  • Sites
  • Innovation.org
  • MAT.org
  • PhRMA.org

Search in PhRMA

  • All
  • News
  • Resources
  • Blogs
Search
Explore Policy Issues
  • Patient Centered Agenda
  • Ecosystem Readiness
    • Beating COVID-19
    • Pandemic Preparedness
  • 340B
  • Access to Medicines
    • Cost and Value of Medicine
    • Insurance Coverage
    • Price Setting
    • Insulin
  • Drug Importation
  • Drug Shortages
  • Intellectual Property
  • International
  • Medicaid
  • Medicare
    • Part B
    • Part D
    • CMMI
  • Prescription Drug Abuse
  • Research & Development
    • R&D Policy Framework
    • FDA
    • PDUFA
    • Venture Capital
    • Manufacturing & Supply Chain
  • STEM
  • Trade

+Share This

Share This

RESEARCH & DEVELOPMENT

FDA Modernization

The United States leads the world in the introduction of new medicines thanks in part to the human drug review program by the U.S. Food and Drug Administration (FDA). To ensure the Agency keeps pace with scientific discovery and to enable a more competitive, innovative and sustainable ecosystem, we need to modernize the FDA.

Pro-patient, pro-science, pro-market reforms at the FDA would enhance the competitive market for biopharmaceuticals, drive efficiency in drug development and discovery and help hold down costs. PhRMA suggests policy solutions in three areas for modernizing drug discovery, development and approval:

Encourage Use of 21st Century Tools for Drug Evaluation, Review and Approval

Scientific advances are re-shaping our understanding of the causes of disease, creating new avenues of research, exploration and discovery. New and powerful tools emphasize individual patient characteristics and include innovative clinical trial design, advanced statistical methods and use of real-world evidence.

Ensure FDA Drug Approval Is Scientifically Sound and Efficient

Medical and basic science is advancing at a breathtaking rate. New developments – including those in immunologic and cell therapies, personalized medicine and regenerative medicine – hold the promise of treating debilitating diseases such as Alzheimer’s, cancer, diabetes and many rare disorders.

Reduce the Generic Backlog and Incentivize Competition Where Needed

A generic drug enters the market at the end of an innovative medication’s lifecycle. When it does, the FDA allows the manufacturer to submit an Abbreviated New Drug Application (ANDA), which does not require repetition of time consuming and costly clinical trials. As a result, generics can enter the market at a fraction of the price of an innovator medicine. With nearly 91 percent of all U.S. retail prescriptions filled with generics, their timely approval is critical to patient access and the long-term sustainability of our health care system.

-

Policy Paper

Policy Solutions

-

Graphic

The Dangers of Drug Importation: Counterfeit Cancer Drugs

Graphic of two speech bubbles with three dots in each

-

Press release

Statement on Workforce Authorities Modernization Act

Related Content

Biologics & Biosimilars

Read More

Regulatory Harmonization

Read More
Medicine Safety

Medicine Safety

Read More

Clinical Trials

Read More

Latest From The Blog

  • Why drug importation is bad for Americans

    by on 5/12/2022 10:43:58 AM

  • Annual projections from NHE compared to actual health care spending

    by on 5/5/2022 11:49:45 AM

  • Study finds insurance barriers disproportionately burden patients with chronic illness

    by on 5/4/2022 3:10:15 PM

  • A conversation with Barry Greene, CEO of Sage Therapeutics

    by on 5/4/2022 9:35:30 AM

PhRMA.Org is now loading ...

Stay Connected

Share

PhRMA Foundation logo
The Voters for Cures logo - Voters for Cures - an initiative from PhRMA
Medicine Assistance Tool logo

  • Members Site
  • Contact Us
  • Privacy Policy
  • Terms of Service
  • Site Map

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."